This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intercept (ICPT) Q4 Earnings & Sales Beat, Ocaliva in Focus
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the fourth quarter and sales beat estimates.
Intercept Pharmaceuticals (ICPT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 2.38% and 0.56%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -60% and 32.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of -20.45% and 14.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viking (VKTX) Study on X-ALD Put on Clinical Hold by the FDA
by Zacks Equity Research
Viking (VKTX) phase Ib study on VK0214 in patients with X-ALD put on hold by the FDA.
Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases
by Zacks Equity Research
Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.
Intercept (ICPT) Down on Withdrawal of Application for NASH
by Zacks Equity Research
Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.
Is the Options Market Predicting a Spike in Intercept (ICPT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.
Intercept (ICPT) Down 10.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Intercept (ICPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Intercept (ICPT) Beats on Q3 Earnings & Sales, Ups View
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the third quarter and sales beat estimates.
Intercept Pharmaceuticals (ICPT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 37.00% and 11.27%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Viatris (VTRS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Viatris' (VTRS) Q3 earnings might have gained from the solid performance of Viagra, Dymista, and the Thrombosis portfolio.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Wall Street Analysts Think Intercept (ICPT) Could Surge 95%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Intercept (ICPT) points to a 94.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Intercept's (ICPT) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss in the second quarter and sales beat estimates.
Intercept Pharmaceuticals (ICPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 73.39% and 16.86%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intercept (ICPT) Moves 8% Higher: Will This Strength Last?
by Zacks Equity Research
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Intercept (ICPT) Ocaliva's Prescribing Information Updated
by Zacks Equity Research
Intercept's (ICPT) PBC drug Ocaliva's label updated due to worsening of liver problems in some patients with cirrhosis.
Intercept (ICPT) Q1 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Intercept (ICPT) posts a narrower loss for the first quarter. Also, sales surpass expectations. However, Ocaliva's safety label remains a concern.
Intercept Pharmaceuticals (ICPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Intercept (ICPT) delivered earnings and revenue surprises of 20.26% and 1.05%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Intercept Pharmaceuticals (ICPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Intercept (ICPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.